Skip to main content

Table 1 Study group averages of SUVBW and tissue-to-muscle (TiMr) and tissue-to-blood (TiBr) ratios (±2 SD) at 2 h and 4 h p.i. for various tissues

From: Pharmacokinetic modeling of a novel hypoxia PET tracer [18F]HX4 in patients with non-small cell lung cancer

Tissue type SUVBW TiMr TiBr
2 h 4 h 2 h 4 h 2 h 4 h
Fat 0.27 ± 0.07 0.18 ± 0.08 0.29 ± 0.05 0.28 ± 0.09 0.28 ± 0.06 0.27 ± 0.10
Liver 1.28 ± 0.40 1.02 ± 0.23 1.54 ± 0.61 1.93 ± 1.12 1.48 ± 0.62 1.88 ± 0.89
Lung 0.24 ± 0.11 0.16 ± 0.10 0.25 ± 0.08 0.24 ± 0.12 0.24 ± 0.08 0.23 ± 0.09
Muscle 0.95 ± 0.28 0.67 ± 0.34 0.96 ± 0.18 0.98 ± 0.28
Tumor 0.93 ± 0.56 0.72 ± 0.56 0.98 ± 0.46 1.09 ± 0.82 0.93 ± 0.35 1.02 ± 0.45
Tumor, viable 1.07 ± 0.63 0.86 ± 0.67 1.12 ± 0.49 1.29 ± 0.98 1.07 ± 0.36 1.21 ± 0.52
Tumor, high 1.22 ± 0.75 1.04 ± 0.83 1.28 ± 0.71 1.61 ± 1.58 1.22 ± 0.54 1.50 ± 0.96
Tumor, mid 0.96 ± 0.66 0.74 ± 0.54 1.00 ± 0.55 1.12 ± 0.79 0.95 ± 0.43 1.05 ± 0.39
Tumor, low 0.39 ± 0.52 0.33 ± 0.40 0.43 ± 0.59 0.62 ± 1.04 0.41 ± 0.51 0.55 ± 0.70